

## imSAVAR Stakeholder Workshop

# Integrating Patient Preferences in Nonclinical Assessment of Immunomodulatory Therapies – Shifting the Paradigm

WORKSHOP PROGRAMME	
26 January 2022 (Day 1)*	27 January 2022 (Day 2)*
<p><b>13:30-14:00 Welcome &amp; Introduction to Workshop</b> (30min)            Chair: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer Institute for Cell Therapy and Immunology (IZI))            Chair: Jonathan Moggs (imSAVAR Project Leader, Novartis Institutes for Biomedical Research (NIBR))</p> <p><b>13:30-13:40 imSAVAR overview</b> (10min)            Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)</p> <p><b>13:40-13:50 Patient engagement in early drug development</b> (10min)            Speaker: Jan Geissler (WECAN Chair, CML Advocates Network (CML))</p> <p><b>13:50-14:00 An imSAVAR model grading system</b> (10min)            Speaker: Scott Wagers (BioSci Consulting)</p> <p><b>14:00-14:40 Adverse events (AEs) of immuno-oncology therapies in detail</b> (30min)            Speaker: Michel Obeid (Centre Hospitalier Universitaire Vaudois (CHUV))            Q &amp; A (10min)</p> <p><b>14:40-15:10 Nonclinical assessments for immuno-oncology therapies in detail</b> (30min)            Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)            Q &amp; A (10min)</p>	<p><b>14:00-14:40 Patient preferences in drug development – PREFER approach</b> (30min)            Speaker: Conny Berlin (IMI PREFER Project Leader, Novartis)            Q &amp; A (10min)</p> <p><b>14:40-16:10 How to integrate patient preferences in the imSAVAR Model Grading System?</b> (90min)            Moderator: Scott Wagers</p> <p><b>14:40-14:55 Scene setting</b> (15min)            Speaker: Scott Wagers (BioSci Consulting)</p> <p><b>14:55-16:10 Panel discussion</b> (75min)            Panelists:</p> <ul style="list-style-type: none"> <li>▪ Gilliosa Spurrier-Bernard (MPNE)</li> <li>▪ Bettina Ryll (MPNE, Horizon Europe Cancer Mission Board Member)</li> <li>▪ Alfonso Aguarón (LuCE)</li> <li>▪ Jan Geissler (WECAN Chair, CML)</li> <li>▪ Michael Hudecek (Universitätsklinikum Würzburg (UKW), IMI T2EVOLVE Project Coordinator)</li> <li>▪ Kristin Reiche (Fraunhofer IZI)</li> <li>▪ Miriam Alb (UKW)</li> <li>▪ Madalena Cipriano (Tübinger Universitätsklinikum)</li> <li>▪ Jonathan Moggs (imSAVAR Project Leader, NIBR)</li> <li>▪ Birgit Fogal (Boehringer Ingelheim)</li> <li>▪ Conny Berlin (IMI PREFER Project Leader, Novartis)</li> </ul>
<b>15:10-15:30 Coffee Break</b>	
<p><b>15:30-16:50 Patient perspectives on immune-related adverse events (irAEs)</b> (80min)            Chair: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI)</p> <p><b>15:30-15:50 Patient perspectives on irAEs attributed to melanoma</b> (10min)            Speaker: Gilliosa Spurrier-Bernard (Melanoma Patients Network Europe (MPNE))            Speaker: Bettina Ryll, (MPNE, Horizon Europe Cancer Mission Board Member)            Q &amp; A (10min)</p> <p><b>15:50-16:10 Patient perspectives on irAEs attributed to lung cancer</b> (10min)            Speaker: Alfonso Aguarón (Lung Cancer Europe (LuCE))            Q &amp; A (10min)</p> <p><b>16:10-16:30 Patient perspectives on irAEs attributed to leukaemias</b> (10min)            Speaker: Jan Geissler (WECAN Chair, CML)            Q &amp; A (10min)</p> <p><b>16:30-16:50 Patient perspectives on irAEs attributed to myeloma</b> (10min)            Speaker: Hans Scheurer (Myeloma Patient Europe)            Q &amp; A (10min)</p> <p><b>16:50-17:00 Wrap-up of Day 1 and Overview of Day 2 programme</b> (10min)</p>	<p><b>16:10-16:30 Concluding remarks</b> (20min)            Speaker: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI)            Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)</p>

\*The Workshop Programme is subject to change. A recording of the Workshop will be available after the event. All timing are in CET.